If you are a biotech founder, your conference budget is a real line item, and most of the events pitched to you are a waste of both money and calendar. The trick is knowing which rooms actually contain the investors and partners you need, and skipping the rest.
This is a shortlist built around one question: which conferences move a fundraise or a partnership forward? Networking for its own sake does not make the cut.
The one everyone builds their year around
The J.P. Morgan Healthcare Conference week in January is the gravitational center of biotech finance. The main event is invitation-only, but the week around it, and especially Biotech Showcase at the Hilton Union Square, is where emerging companies present to and meet with investors at scale. If you are going to do exactly one thing in January, do JPM week. Book meetings in November; the calendar is full by December.
Investor and partnering events worth the flight
Beyond JPM, a handful of events are engineered specifically around the founder-investor connection rather than science or trade.
- BIO CEO & Investor Conference puts management teams in front of the investment community early in the year. Practical, deal-oriented, and less overwhelming than the June mega-convention.
- LSX World Congress in London is the anchor event for European biotech financing and a strong choice if your investor base or expansion plans point across the Atlantic.
- RESI (Redefining Early Stage Investments) is built for the earliest-stage companies, matching seed and Series A founders with the specific investors who write those checks. It runs several times a year in different cities.
- BIO Investor Forum in the fall is a focused public-and-private financing event, useful if you missed the January window.
- Bio€quity Europe gathers European CEOs and investors for a smaller, higher-signal partnering meeting.
The partnering machine: when you are ready for pharma
Fundraising and partnering are different sports. Once you have an asset a pharma company might want, the partnering-heavy events earn their keep:
- BIO International Convention (June, San Diego in 2026) runs the largest one-to-one partnering system in the industry, with tens of thousands of scheduled meetings. If you need business development volume, nothing else compares.
- BIO-Europe and BIO-Europe Spring are the European equivalents, and the fall edition in particular draws serious dealmakers.
The mistake founders make is treating these as fundraising events. They are licensing and BD events. Show up with a data package and a partnering strategy, not a pitch deck asking for a Series B.
How to pick, when your budget only covers two or three
Match the event to the stage you are actually at:
- Pre-seed to seed: RESI, plus JPM week if you can get meetings. Focus on the investors who write first checks; do not waste time in rooms full of crossover funds that only invest at the crossover.
- Series A to B, still private: JPM week, BIO CEO & Investor, and LSX if Europe is in play.
- Have an asset pharma wants: BIO International and BIO-Europe for partnering, in addition to your financing events.
Then be ruthless. Two well-prepared conferences beat five where you wander the floor collecting badges.
The unglamorous part: preparation beats attendance
The founders who raise at conferences are not the ones with the best booth. They are the ones who did the homework. That means researching which investors will attend, identifying the ones whose stage and sector actually fit, and requesting specific meetings weeks ahead. It means a two-minute version of your story that you can deliver without notes, and a clear ask at the end of every conversation. And it means following up within 48 hours, while you are still a face and not a business card.
A conference does not raise your round. It compresses a quarter of investor outreach into three days, if you prepare like it.
Map the whole year before you commit
Regional and specialist events worth a look
The marquee events get the attention, but some of the highest-signal fundraising happens at smaller, focused gatherings. Regional life-science organizations run investor days that concentrate the local ecosystem, which matters if your investors are geographically clustered. Modality- and disease-specific meetings, from cell and gene therapy to a particular rare disease, put you in front of the specialist investors who understand your science well enough to move quickly. And European events like Bio€quity Europe and the Swiss and Nordic gatherings are worth the trip if your cap table skews, or needs to skew, transatlantic. The general rule holds: a smaller room full of the right investors beats a huge room full of the wrong ones.
The events to be skeptical of
Not every “biotech investor summit” in your inbox is worth the registration fee. Be wary of events that charge founders large sums to present but cannot tell you which investors will actually attend, generic innovation conferences with a thin biotech track bolted on, and anything that promises guaranteed investor meetings for a fee. Real partnering systems match on fit and mutual interest; pay-to-pitch schemes rarely deliver the caliber of investor you need. Before committing, ask the organizer for a concrete list of the investor firms that attended last year. If they dodge, so should you.
Attending versus sponsoring
One more decision: at the events that matter to you, is it worth sponsoring rather than just attending? For an early company, usually not, the money is better spent on the raise itself. But once you have a story to tell at scale, or a service to sell into the industry, a well-placed sponsorship can put your name in front of exactly the audience you want. The calculus is different for a founder raising a round than for a service provider building a brand, so be clear which game you are playing before you write the check.
Time your calendar to your raise
The last piece of conference strategy is sequencing. Because January’s JPM week sets the tone for the year, many founders aim to have their materials polished and their first meetings underway by then, using the week to open relationships that mature into a spring raise. If you miss that window, the fall partnering and investor circuit offers a second on-ramp. The mistake is treating conferences as isolated events rather than nodes in a continuous fundraising campaign: the meeting you take in January should connect to the follow-up in February and the term sheet in the spring. Map your target events against your intended raise timeline, work backward from when you need the money in the bank, and treat the whole year’s calendar as one coordinated push rather than a series of disconnected trips.
One last thing: send the right person
Who attends matters as much as which event you pick. Investors at a fundraising conference want to meet a founder or CEO who can speak to both the science and the business, not a delegate who has to check on every question. If your raise depends on a scientific story, the person in the room needs to own that story cold. For a small company, that usually means the CEO goes, full stop, and treats the week as a core part of the job rather than a delegation. The relationships that get built at these events are personal, and investors are, in part, deciding whether they want to spend the next seven years on a board with you.
Conference spending adds up fast, so it pays to see the full calendar before you decide where to plant your flag. The BioMed Nexus conferences directory lets you filter every major 2026 event by category, including a dedicated investor and partnering track, so you can build a calendar around your raise instead of around whatever invitation lands in your inbox. And the daily brief keeps you current on which investors are actually deploying capital right now, which is half the battle.
Frequently asked questions
What is the best biotech conference for raising money?
For most biotechs, J.P. Morgan Healthcare Conference week in January, and especially Biotech Showcase, is the single best fundraising event because it concentrates the investor community in one place. LSX World Congress, RESI, and BIO CEO & Investor are strong complements depending on stage and geography.
What is the difference between a fundraising and a partnering conference?
Fundraising conferences connect companies with investors who provide capital, while partnering conferences connect companies with pharma partners for licensing and collaboration deals. JPM and RESI lean fundraising; BIO International and BIO-Europe are partnering machines built around one-to-one meetings.
Which biotech conference is best for early-stage startups?
RESI is designed specifically for seed and Series A companies, matching early founders with investors who write first checks. JPM week is also valuable if you can secure meetings in advance. Very early founders should prioritize events where first-check investors actually attend.
